Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 21Neoplasms 16Neuroblastoma 14Small Cell Lung Carcinoma 13Carcinoma, Ovarian Epithelial 12Fallopian Tube Neoplasms 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Lung Neoplasms 10Recurrence 8Leukemia 8Leukemia, Myeloid, Acute 7Uterine Cervical Neoplasms 6Unspecified Adult Solid Tumor, Protocol Specific 6Neoplasm Metastasis 6Lymphoma 6Sarcoma, Ewing 5Endometrial Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Brain Neoplasms 5Sarcoma 4Lymphoma, Follicular 4Glioma 4Central Nervous System Neoplasms 4Burkitt Lymphoma 4Blast Crisis 4Rhabdomyosarcoma 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Myelodysplastic Syndromes 3Meningeal Carcinomatosis 3Medulloblastoma 3

Interventions

palbociclib 2duvelisib 2berzosertib 2Fulvestrant 2Everolimus 2volagidemab 1serabelisib 1ribociclib 1pembrolizumab 1olaparib 1obinutuzumab 1lorlatinib 1gedatolisib 1encorafenib 1cobimetinib 1chiauranib 1capivasertib 1binimetinib 1Topotecan 1Radiotherapy 1Panobinostat 1PX-866 1NVP-BKM120 1Letrozole 1Cetuximab 1CYH33 1BAY 1895344 1AZD1390 12-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Hereditary Sensory and Autonomic Neuropathies × Topotecan × Clear all
NCT05246111 2024-11-22

Berzosertib Human Mass Balance Study (DDRiver Solid Tumors 208)

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Phase 1 Completed
6 enrolled 30 charts

Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡